UBS Group AG lifted its position in shares of Invivyd, Inc. (NASDAQ:IVVD – Free Report) by 683.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,050,923 shares of the company’s stock after purchasing an additional 916,842 shares during the quarter. UBS Group AG’s holdings in Invivyd were worth $2,596,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. RA Capital Management L.P. bought a new position in shares of Invivyd during the third quarter worth $18,831,000. ADAR1 Capital Management LLC bought a new position in shares of Invivyd during the third quarter worth $8,108,000. Vanguard Group Inc. boosted its position in shares of Invivyd by 46.7% during the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after purchasing an additional 1,834,970 shares in the last quarter. Millennium Management LLC boosted its position in shares of Invivyd by 15.8% during the third quarter. Millennium Management LLC now owns 1,446,615 shares of the company’s stock worth $1,591,000 after purchasing an additional 197,522 shares in the last quarter. Finally, Boothbay Fund Management LLC bought a new position in shares of Invivyd during the third quarter worth $894,000. 70.36% of the stock is owned by institutional investors.
Invivyd Stock Performance
IVVD opened at $1.10 on Wednesday. The stock has a market capitalization of $324.07 million, a P/E ratio of -3.55 and a beta of 0.71. Invivyd, Inc. has a 12 month low of $0.48 and a 12 month high of $3.07. The firm’s fifty day simple moving average is $1.42 and its 200 day simple moving average is $1.87.
Analyst Ratings Changes
A number of brokerages have recently weighed in on IVVD. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. BTIG Research reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Invivyd in a research report on Monday, May 18th. HC Wainwright reaffirmed a “buy” rating on shares of Invivyd in a research report on Thursday, May 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a research report on Wednesday, April 29th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $8.00.
View Our Latest Stock Report on Invivyd
About Invivyd
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Featured Stories
- Five stocks we like better than Invivyd
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Want to see what other hedge funds are holding IVVD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Invivyd, Inc. (NASDAQ:IVVD – Free Report).
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
